GIGA 2021 Annual Report 69 SELECTED PUBLICATIONS DHX15-independent roles for TFIP11 in U6 snRNA modifications, U4/U6.U5 tri-snRNP assembly and pre-mRNA splicing fidelity. Duchemin A., O’Grady T., Hanache S., Mereau A., Thiry M., Wacheul L., Michaux C., Perpète E., Hervouet E., Peixoto P., Ernst FGM., Audic Y., Dequiedt F., Lafontaine DLJ., Mottet D. Nature Communications, 12(1) (2021), 6648. Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma. Van Hulst G., Jorssen J., Jacobs N., Henket M., Louis R., Schleich F., Bureau F., Desmet C. Eur Respir J., (2021). Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Luis G., Godfroid A., Nishiumi S., Cimino J., Blacher S., Maquoi E, Wery C., Collignon A., Longuespée R., Montero-Ruiz L., Dassoul I., Maloujahmoum N., Pottier C, Mazzucchelli G., Depauw E., Bellhacene A., Yoshida M., Noel A, Sounni N. Redox Biology 43 (2021). A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Elodie Duray, Margaux Lejeune, Frederic Baron, Yves Beguin, Nick Devoogdt, Ahmet Krasniqi, Yoline Lauwers, Yong Juan Zhao, Matthias D’Huyvetter, Mireille Dumoulin and Jo Caers. J Hematol Oncol (2021). Wobble tRNA modification and hydrophilic amino acid patterns dictate protein fate. Francesca Rapino, Zhaoli Zhou, Ana Maria Roncero Sanchez, Marc Joiret, Christian Seca, Najla El Hachem, Gianluca Valenti, Sara Latini, Kateryna Shostak, Liesbet Geris, Ping Li, Gang Huang, Gabriel Mazzucchelli, Dominique Baiwir, Christophe J. Desmet, Alain Chariot, Michel Georges, Pierre Close. Nature Communications 12, Article number: 2170 (2021). ORGENESIS Cell and gene therapies use modified cells or cellular matter to treat, prevent or cure serious health issues like cancer, genetic disorders, immunodeficiencies, rare diseases, and more. Orgenesis Point of Care Platform is shaping a cell and gene therapy ecosystem to lower costs for innovators, accelerate treatments to market, and expand access for patients. For one of its therapies in development, Orgenesis is interested in using patient Mesenchymal Stem Cells (MSC) from various sources of tissues. Hence, Anne Christine Hick, head of R&D laboratory in Belgium, and her team were interested in identifying if the cells expressed specific MSC markers. Orgenesis therefore established a collaboration with the GIGA Cell Imaging platform to perform FASC analysis. This collaboration was very proficient. Using the FACS CANTO system and a commercial kit for MCS markers, we showed that our cells expressed at minimum 97% positive MCS markers CD90, CD105 and CD73, and less that 2% negative markers such as CD34, CD11b, CD19 and HLA-DR of MSC. GIGA platform provided all results and reports in a detailedmanner. Additionally, FabioGrieco, laboratoryofficer inR&D department in Belgium, had the opportunity to spend a training day at GIGA and follow the activity preformed on samples preparation and subsequent FASC analysis.
RkJQdWJsaXNoZXIy MTk1ODY=